Table 5.
Multivariable adjusted* odds ratio (OR) and 95% confidence interval (CI) for triple negative and luminal A breast cancer associated with oral contraceptives by p53 status
No. controls |
No. cases | OR (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|---|
Triple negative/p53+ |
Triple negative/p53− |
Luminal A/p53+ |
Luminal A/p53− |
Triple negative/p53+ | Triple negative/p53− | Luminal A/p53+ | Luminal A/p53− | ||
Oral contraceptive use | |||||||||
Never use | 410 | 26 | 33 | 21 | 134 | Reference | Reference | Reference | Reference |
Ever use | 1605 | 125 | 151 | 91 | 399 | 0.98 (0.61–1.57) | 1.05 (0.69–1.61) | 1.18 (0.70–2.01) | 0.89 (0.70–1.14) |
Test for homogeneity P-value | 0.74 | ||||||||
Duration of use, years | |||||||||
<1 | 358 | 22 | 35 | 17 | 99 | 0.78 (0.43–1.44) | 1.12 (0.67–1.87) | 1.00 (0.50–1.97) | 0.99 (0.72–1.35) |
1–4 | 540 | 34 | 52 | 40 | 139 | 0.79 (0.45–1.39) | 1.08 (0.66–1.76) | 1.62 (0.89–2.93) | 0.96 (0.71–1.29) |
5–9 | 396 | 41 | 34 | 16 | 85 | 1.33 (0.77–2.29) | 0.97 (0.57–1.65) | 0.87 (0.43–1.77) | 0.77 (0.55–1.06) |
≥10 | 311 | 28 | 30 | 18 | 76 | 1.14 (0.64–2.05) | 1.02 (0.60–1.76) | 1.14 (0.57–2.25) | 0.82 (0.59–1.15) |
Trend p-value | 0.17 | 0.85 | 0.92 | 0.09 | |||||
Test for homogeneity of trends P-value | 0.18 | ||||||||
Age at first use, years | |||||||||
≥25 | 399 | 22 | 32 | 22 | 114 | 0.91 (0.50–1.64) | 1.09 (0.65–1.82) | 1.19 (0.63–2.23) | 0.87 (0.65–1.17) |
20–24 | 569 | 36 | 53 | 40 | 154 | 0.86 (0.49–1.51) | 1.10 (0.67–1.80) | 1.48 (0.81–2.73) | 0.97 (0.72–1.31) |
18–19 | 332 | 37 | 25 | 15 | 65 | 1.33 (0.74–2.40) | 0.75 (0.41–1.36) | 0.86 (0.41–1.83) | 0.78 (0.54–1.14) |
<18 | 305 | 30 | 41 | 14 | 66 | 1.03 (0.55–1.93) | 1.22 (0.69–2.14) | 0.89 (0.41–1.96) | 0.90 (0.61–1.34) |
Trend p-value | 0.60 | 0.81 | 0.66 | 0.43 | |||||
Test for homogeneity of trends P-value | 0.77 | ||||||||
Duration between menarche and first use, years | |||||||||
<5 | 264 | 25 | 33 | 14 | 48 | 0.90 (0.46–1.74) | 1.13 (0.62–2.07) | 0.93 (0.42–2.07) | 0.76 (0.49–1.16) |
5–9 | 662 | 60 | 59 | 35 | 153 | 1.05 (0.62–1.79) | 0.91 (0.55–1.49) | 0.99 (0.53–1.86) | 0.85 (0.63–1.17) |
10–14 | 437 | 25 | 39 | 27 | 125 | 0.85 (0.47–1.54) | 1.12 (0.67–1.85) | 1.35 (0.73–2.50) | 0.97 (0.72–1.30) |
≥15 | 242 | 15 | 20 | 15 | 73 | 1.08 (0.55–2.10) | 1.13 (0.63–2.03) | 1.34 (0.67–2.69) | 0.89 (0.63–1.24) |
Trend p-value | 0.99 | 0.75 | 0.26 | 0.70 | |||||
Test for homogeneity of trends P-value | 0.65 | ||||||||
Time since last use, years | |||||||||
<5 | 165 | 15 | 14 | 10 | 34 | 1.06 (0.51–2.23) | 0.71 (0.35–1.45) | 1.17 (0.49–2.78) | 0.72 (0.45–1.15) |
5–9 | 116 | 14 | 13 | 7 | 32 | 1.39 (0.66–2.96) | 0.97 (0.47–2.01) | 1.23 (0.48–3.19) | 1.09 (0.67–1.76) |
10–14 | 219 | 23 | 22 | 9 | 59 | 1.21 (0.63–2.30) | 0.92 (0.50–1.69) | 0.80 (0.34–1.89) | 1.02 (0.69–1.51) |
15–19 | 327 | 21 | 30 | 19 | 67 | 0.81 (0.43–1.54) | 0.96 (0.55–1.67) | 1.20 (0.60–2.40) | 0.77 (0.54–1.10) |
≥20 | 778 | 52 | 72 | 46 | 207 | 0.93 (0.56–1.56) | 1.18 (0.75–1.85) | 1.24 (0.71–2.18) | 0.91 (0.70–1.19) |
Trend p-value | 0.53 | 0.31 | 0.48 | 0.53 | |||||
Test for homogeneity of trends P-value | 0.46 |
Note: Triple negative = ER−/PR−/HER2−, Luminal A = ER+ or PR+ plus HER2−.
Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, menopausal status, body mass index, parity.